ドライアイ症候群治療薬の世界市場予測および分析（～2024）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 8
1.1 List of Tables 14
1.2 List of Figures 17
2 Introduction 19
2.1 Related Reports 19
3 Disease Overview 21
3.1 Etiology and Pathophysiology 21
3.1.1 Etiology 21
3.1.2 Pathophysiology 24
3.2 Disease Classification 26
3.3 Symptoms 27
3.4 Prognosis 30
3.5 Quality of Life 31
4 Epidemiology 32
4.1 Risk Factors and Comorbidities 32
4.1.1 Risk of Dry Eye Syndrome Increases 35% Each Decade after Age 40 33
4.1.2 Women are twice as likely to have Dry Eye Syndrome as men 33
4.1.3 Use of certain medications may increase the risk of developing Dry Eye Syndrome 34
4.1.4 Diets rich in Omega-3 fatty acid may prevent dry eye syndrome 35
4.1.5 Certain environmental conditions can double the risk of Dry Eye Syndrome 35
4.2 Global Trends 36
4.2.1 US 36
4.2.2 5EU 36
4.2.3 Asia 37
4.3 Forecast Methodology 38
4.3.1 Sources used 39
4.3.2 Forecast Assumptions and Methods -Total Prevalent Cases of Dry Eye Syndrome 41
4.3.3 Sources Not Used 44
4.4 Epidemiology Forecast for Dry Eye Syndrome (2014-2024) 44
4.4.1 Total Prevalent Cases of Dry Eye Syndrome 44
4.4.2 Age-Specific Total Prevalent Cases 46
4.4.3 Sex-Specific Total Prevalent Cases 48
4.4.4 Age-Standardized Total Prevalence of Dry Eye Syndrome 50
4.4.5 Total Prevalent Cases of Dry Eye Syndrome by Severity 51
4.5 Discussion 52
4.5.1 Conclusions on Epidemiology Trends 52
4.5.2 Limitations of Analysis 53
4.5.3 Strengths of Analysis 54
5 Disease Management 55
5.1 Diagnosis and Treatment Overview 55
5.1.1 Diagnosis 55
5.1.2 Treatment Guidelines 58
5.1.3 Clinical Practice 59
5.2 US 65
5.3 5EU 69
5.4 Japan 74
5.5 China 76
5.6 India 78
6 Competitive Assessment 82
6.1 Overview 82
6.2 Product Profiles 83
6.2.1 Restasis (cyclosporine) 83
6.2.2 Diquas (diquafosol tetrasodium) 93
6.2.3 Mucosta ophthalmic solution (rebamipide) 99
6.2.4 Ikervis (cyclosporine) 104
6.2.5 Artificial Tears 111
6.2.6 Other therapies 119
7 Unmet Need and Opportunity 124
7.1 Overview 124
7.2 New Therapies for DES 126
7.2.1 Unmet Need 126
7.2.2 Gap Analysis 127
7.2.3 Opportunity 129
7.3 Better Diagnostic Tools 130
7.3.1 Unmet Need 130
7.3.2 Gap Analysis 131
7.3.3 Opportunity 133
7.4 Appropriate Clinical Trial Design to Secure Regulatory Approval 134
7.4.1 Unmet Need 134
7.4.2 Gap Analysis 136
7.4.3 Opportunity 137
7.5 Simplified Dosing 138
7.5.1 Unmet Need 138
7.5.2 Gap Analysis 139
7.5.3 Opportunity 140
7.6 Patient Education to Improve Tolerance and Compliance 140
7.6.1 Unmet Need 140
7.6.2 Gap Analysis 142
7.6.3 Opportunity 143
7.7 Improved Physician and Patient Disease Awareness 143
7.7.1 Unmet Need 143
7.7.2 Gap Analysis 145
7.7.3 Opportunity 145
8 Pipeline Assessment 146
8.1 Overview 146
8.2 Clinical Trial Mapping 147
8.2.1 Clinical Trial Design for DES 148
8.2.2 Ora for DES Drug Development 149
8.3 Promising Drugs in Clinical Development 150
8.3.1 Lifitegrast 152
8.3.2 Tavilermide 161
8.3.3 Visomitin 167
8.3.4 RGN-259 173
8.3.5 Cis-UCA 179
8.3.6 SI-614 181
8.4 Promising Drugs in Early-Stage Development 182
8.4.1 KPI-121 182
8.4.2 Ozagrel 183
8.4.3 P-321 184
8.4.4 Dextenza (OTX-DP) 185
8.5 Other Drugs in Development 186
9 Current and Future Players 187
9.1 Overview 187
9.2 Trends in Corporate Strategy 188
9.3 Company Profiles 189
9.3.1 Alcon 189
9.3.2 Allergan 190
9.3.3 Herantis 193
9.3.4 Mimetogen 194
9.3.5 Mitotech 195
9.3.6 Otsuka 196
9.3.7 RegeneRx 198
9.3.8 Santen 201
9.3.9 Shire 203
10 Market Outlook 206
10.1 Global Markets 206
10.1.1 Forecast 206
10.1.2 Drivers and Barriers – Global Issues 213
10.2 US 213
10.2.1 Forecast 213
10.2.2 Key Events 217
10.2.3 Drivers and Barriers 217
10.3 5EU 218
10.3.1 Forecast 218
10.3.2 Key Events 222
10.3.3 Drivers and Barriers 222
10.4 Japan 224
10.4.1 Forecast 224
10.4.2 Key Events 226
10.4.3 Drivers and Barriers 227
10.5 China 227
10.5.1 Forecast 227
10.5.2 Key Events 229
10.5.3 Drivers and Barriers 230
10.6 India 230
10.6.1 Forecast 230
10.6.2 Drivers and Barriers 233
11 Appendix 234
11.1 Bibliography 234
11.2 Abbreviations 267
11.3 Methodology 271
11.4 Forecasting Methodology 271
11.4.1 Diagnosed DES Patients 271
11.4.2 Percent Drug-Treated Patients 271
11.4.3 Launch Dates 272
11.4.4 General Pricing Assumptions 272
11.4.5 Individual Drug Assumptions 273
11.4.6 Pricing of Pipeline Agents 276
11.5 Primary Research – KOLs Interviewed for this Report 277
11.6 Primary Research – High-prescriber Survey 279
11.7 About the Authors 280
11.7.1 Analyst 280
11.7.2 Therapy Area Director 280
11.7.3 Epidemiologist 281
11.7.4 Global Head of Healthcare 281
11.8 About GlobalData 282
11.9 Disclaimer 282